Omeros (OMER) Lifted to Hold at ValuEngine

ValuEngine upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a report issued on Friday.

Other equities analysts also recently issued reports about the stock. Maxim Group set a $24.00 price objective on shares of Omeros and gave the company a buy rating in a research note on Monday, January 22nd. HC Wainwright set a $30.00 price objective on shares of Omeros and gave the company a buy rating in a research note on Wednesday, November 29th. Needham & Company LLC downgraded shares of Omeros from a buy rating to a hold rating and set a $9.01 price objective for the company. in a research note on Friday, March 2nd. Finally, Cantor Fitzgerald set a $19.00 price objective on shares of Omeros and gave the company a hold rating in a research note on Thursday, March 1st. Two analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Omeros presently has a consensus rating of Hold and an average price target of $25.88.

How to Become a New Pot Stock Millionaire

Shares of Omeros (OMER) opened at $14.09 on Friday. The company has a debt-to-equity ratio of -29.93, a current ratio of 4.12 and a quick ratio of 4.10. The firm has a market cap of $760.50, a price-to-earnings ratio of -12.04 and a beta of 3.57. Omeros has a one year low of $8.36 and a one year high of $27.09.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The business had revenue of $13.76 million for the quarter, compared to analyst estimates of $21.94 million. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.45) earnings per share. equities analysts anticipate that Omeros will post -0.76 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Ingalls & Snyder LLC raised its stake in shares of Omeros by 3.4% during the fourth quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock valued at $103,664,000 after acquiring an additional 174,204 shares during the last quarter. Wedbush Securities Inc. raised its stake in Omeros by 32.4% in the fourth quarter. Wedbush Securities Inc. now owns 94,923 shares of the biopharmaceutical company’s stock worth $1,844,000 after buying an additional 23,241 shares in the last quarter. Swiss National Bank raised its stake in Omeros by 11.9% in the third quarter. Swiss National Bank now owns 75,100 shares of the biopharmaceutical company’s stock worth $1,624,000 after buying an additional 8,000 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Omeros by 10.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,804 shares of the biopharmaceutical company’s stock worth $4,709,000 after buying an additional 20,139 shares in the last quarter. Finally, Capital Analysts LLC raised its stake in Omeros by 885.6% in the fourth quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock worth $36,125,000 after buying an additional 530,899 shares in the last quarter. 48.56% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Omeros (OMER) Lifted to Hold at ValuEngine” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3295930/omeros-omer-lifted-to-hold-at-valuengine.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

EPAM Systems  Raised to Buy at Zacks Investment Research
EPAM Systems Raised to Buy at Zacks Investment Research
VirnetX   Shares Down 6.3%
VirnetX Shares Down 6.3%
Cleveland-Cliffs   Shares Down 6%
Cleveland-Cliffs Shares Down 6%
Brokerages Expect Badger Meter  to Announce $0.40 EPS
Brokerages Expect Badger Meter to Announce $0.40 EPS
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Citrix Systems  Stock Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Citrix Systems Stock Price
Scripps Networks Interactive  Receives Daily News Impact Score of 0.12
Scripps Networks Interactive Receives Daily News Impact Score of 0.12


© 2006-2018 Ticker Report. Google+.